CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022

Gender-affirming hormonal therapy did not appear to affect cabotegravir concentrations in transgender women in this preliminary analysis from HPTN 083.

Both DTG 50 mg plus 3TC/TDF and EFV 400 mg plus 3TC/TDF regimens effective and safe for treatment-naive PWH in Cameroon, with higher rates of virologic suppression over time and more weight gain observed with DTG-based regimen.

Switching from standard combination ART to DTG plus FTC was noninferior to continuing standard combination ART in virologically suppressed adults through Week 144 in this randomized clinical trial.

Significantly greater proportion of patients with HIV/HBV coinfection achieved HBV DNA <29 IU/mL with BIC/FTC/TAF vs DTG + FTC/TDF at 48 weeks; HIV outcomes were similar with both regimens.

Dual therapy was well tolerated and demonstrated noninferior efficacy vs triple therapy as first-line ART in this open-label, randomized trial conducted in Argentina.

Bedaquiline, pretomanid, and linezolid with or without clofazimine or moxifloxacin for 24 weeks appeared to be generally safe and effective for the treatment of rifampicin-resistant TB in both people with and without HIV in this randomized, open-label phase II/III trial.

PrEP adherence at 12 months improved by 6-month PrEP dispensing and HIV self-testing among single women in Kenya.

VRC01 had no effect on HIV-1 RNA or HIV-1 DNA when given in combination with early ART to infants with HIV.

Doxycycline PEP taken within 72 hours of condomless sex resulted in a substantial reduction in the incidence of gonorrhea, chlamydia, and syphilis in this randomized, open-label study.

An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.